Your browser doesn't support javascript.
loading
Overcoming Lot-to-Lot Variability in Protein Activity Using Epitope-Specific Calibration-Free Concentration Analysis.
Harvey, Ian B; Chilewski, Shannon D; Bhosale, Devyani; Tobia, Sarah E; Gray, Christopher; Gleason, Carol; Haulenbeek, Jonathan.
Afiliación
  • Harvey IB; Translational Sciences and Diagnostics, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.
  • Chilewski SD; Translational Sciences and Diagnostics, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.
  • Bhosale D; Translational Sciences and Diagnostics, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.
  • Tobia SE; Translational Sciences and Diagnostics, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.
  • Gray C; Translational Sciences and Diagnostics, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.
  • Gleason C; Global Biometrics and Data Sciences, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.
  • Haulenbeek J; Translational Sciences and Diagnostics, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.
Anal Chem ; 96(16): 6275-6281, 2024 Apr 23.
Article en En | MEDLINE | ID: mdl-38600735
ABSTRACT
Concentration determination is a fundamental hallmark of protein reagent characterization, providing a means to ensure reproducibility and unify measurements from various assays. However, lot-to-lot differences in protein activity often still occur, leading to uncertainty in the accuracy of downstream measurements. Here, we postulate that those differences are caused by a misrepresentation of the protein concentration as measured by traditional total protein techniques, which can include multiple types of inactive protein species. To overcome this, we developed a standardized method to quantify a protein's active concentration via calibration-free concentration analysis (CFCA). As a pilot study, we compare the biophysical and immunoassay responses from three batches of recombinant soluble lymphocyte-activation gene 3 (sLAG3), as defined by either their total or active concentrations. Defining the sLAG3 reagents by their assay-specific concentration improved consistency in reported kinetic binding parameters and decreased immunoassay lot-to-lot coefficients of variation (CVs) by over 600% compared to the total protein concentration. These findings suggest that the total concentration of a protein reagent may not be the ideal metric to correlate in-assay signals between lots, and by instead quantifying the concentrations of a reagent's assay-specific epitopes, CFCA may prove a useful tool in overcoming lot-to-lot variability.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Anal Chem Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Anal Chem Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos